Results from the Alliance A221304 randomised clinical trial.
ONCOLOGY
Fully funded by 
Content independently selected
-
-
ASCO: new oxaliplatin guidelines for stage III colon cancer Shorter course of adjuvant chemotherapy an option for low-risk patients.
-
Breast cancer: 93% of survivors report persistent health issues A Dutch survey of more than 800 women.
-
NICE says no to osimertinib for EGFR-positive NSCLC The NICE appraisal committee raised a number of issues concerning the clinical evidence
-
NSCLC: pembrolizumab tops chemotherapy at lower PD-L1 cutoff KEYNOTE-042 data led FDA to lower the PD-L1 cutoff.
-
Data from the UK Biobank for half a million men and women aged 40-69 years.
-
Oral cancer: comorbidity status, immune biomarkers predict survival A severe comorbidity quadrupled mortality risk in OSCC, regardless of stage.
-
Childhood hepatoblastoma: minimal adjuvant chemotherapy yields good outcomes Reducing exposure in select patients could help prevent acute and long-term toxicities.
-
Rectal cancer: short-course RT most cost-effective for locally advanced disease Preoperative use indicated barring need for presurgical tumor downstaging.
-
Hodgkin lymphoma: aprepitant reduces vomiting in pediatric patients No significant reduction in incidence of nausea.
-
Final analysis: abiraterone ups survival in high-risk metastatic prostate cancer Data from the LATITUDE phase 3 trial in castration-sensitive disease.
-
MRI criteria for "good-prognosis" patients in rectal cancer Distinguishes who can avoid preoperative chemotherapy.
-
The move has been met with criticism.
-
FDA approves erdafitinib for bladder cancer Companion diagnostic test cleared to identify patients with susceptible FGFR mutations.